UCLA-led investigators say additional research is needed into why guideline-recommended genetic testing remains low among ...

The funding will support the development of Revolution's RAS(ON) inhibitor daraxonrasib in exchange for tiered royalties on its sales.

In a Phase I/II clinical trial, TKI-pretreated NSCLC patients given zidesamtinib had an overall response rate of 44 percent.

In the NEULARK trial, patients with early-stage LRRK2-driven Parkinson's disease will receive Neuron23's NEU-411 or a placebo.

The agency granted the accelerated approval for Datroway in EGFR-mutant NSCLC based on data from the TROPION-Lung05 and TROPION-Lung01 trials.